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Here we report a case of Trichosporon asahii fungaemia in a neutropenic patient with acute leukaemia that did not respond to fluconazole, liposomal amphotericin B and voriconazole treatment. Microbiological eradication of fungaemia was achieved after treatment with caspofungin combined with amphotericin B.
A 54-year-old man was referred to our institution in October 2002 because of occurrence of high fever resistant to broadspectrum antibiotic therapy. He had a 6 month history of acute myeloid leukaemia treated with induction chemotherapy followed by three cycles of aracytine, daunorubicin and etoposide. On admission, physical examination was normal, except for oral candidiasis and fever (39.58C). Laboratory tests disclosed a leucocyte count of 50/mm 3 , a haemoglobin level of 8.7 g/dL and a platelet count of 7000/mm 3 . Galactomannan antigen for Aspergillus and quantitative real-time polymerase chain reaction for cytomegalovirus, as well as routine blood cultures and Mycobacterium tuberculosis cultures, were negative. Treatment with granulocyte-colony stimulating factor 300 mg/day, meropenem 3 g/day, teicoplanin 600 mg/day and fluconazole 400 mg/day was started. On 18 October 2002, three blood cultures yielded Trichosporon spp., which were then identified as Trichosporon asahii (carbohydrate utilization panel, API ID 32 C; bioMérieux, Marcy l'É toile, France). Treatment with liposomal amphotericin B (5 mg/kg/day) was started, fluconazole and teicoplanin were stopped and meropenem was continued. Six days later, due to the persistence of fever (408C) together with T. asahii in blood cultures, amphotericin B was discontinued, and intravenous voriconazole (800 mg/day the first day, then 600 mg/day) started.
The patient remained febrile and blood cultures still yielded T. asahii (Figure 1) . Meanwhile, an increase in the values of bilirubinaemia, transaminases and alkaline phosphatase was observed. Histological examination and microbiological culture of liver biopsy were not diagnostic. Cardiac echography, chest X-rays, cerebral CT scan and funduscopic examination were normal. After 7 days of voriconazole therapy, the patient remained febrile and the hepatic values continued to increase, even though drug dosage was reduced to 400 mg daily. Voriconazole was interrupted, and caspofungin (70 mg the first day then 50 mg/day) in combination with liposomal amphotericin B (5 mg/kg/day) was started. We observed general improvement, as the patient felt better and the fever showed a resolution within 5 days; meanwhile, blood cultures became negative and remained so thereafter. Despite initial improvement, the clinical condition of the patient started to deteriorate, and he died 3 weeks later due to the recurrence of leukaemia. No clinical findings compatible with systemic infection were present. An autopsy was not performed because of the family's refusal.
Amphotericin B has been recommended as the first-line drug in the treatment of trichosporonosis, even though there is no obvious effective treatment for disseminated infections. Anecdotal reports show that azoles (ketoconazole, fluconazole, voriconazole) are sometimes effective in the treatment of trichosporonosis. 2 Limited in vitro data show that caspofungin lacks activity against Trichosporon species.
1 In the treatment of Trichosporon infection, the clinical experience with caspofungin is scanty. Caspofungin has been successfully used in one case of Trichosporon inkin peritonitis associated with peritoneal dialysis.
3 By contrast, a breakthrough invasive trichosporonosis in a bone marrow transplant recipient receiving caspofungin as prophylaxis against Aspergillus infection has been reported. 4 To our knowledge, this is the first case of disseminated Trichosporon infection treated with caspofungin combined with liposomal amphotericin B. In vitro data with caspofungin combined with azoles or amphotericin B have demonstrated synergy or indifference against clinical isolates of Candida spp., Cryptococcus neoformans and Aspergillus spp. 5, 6 Clinical experience with caspofungin in combination with either conventional or liposomal amphotericin B for the treatment of aspergillosis is now accumulating. 5 Combination therapy was well tolerated and a favourable response was observed in a significant proportion of patients (21%-77%) with possible or proven invasive aspergillosis for whom amphotericin B monotherapy had failed. 
Correspondence
Our report underlines the difficulties of treatment of Trichosporon infection in neutropenic patients. Unfortunately, the lack of a post-mortem examination does not allow us to draw firm conclusions. However, in our patient, liposomal amphotericin B and voriconazole were not clinically and microbiologically effective when used as sole antifungal agents. By contrast, the combination therapy with caspofungin and liposomal amphotericin B was found to be effective in eradicating T. asahii from blood, and was also well tolerated and associated with resolution of fever.
Disseminated trichosporonosis is a life-threatening infection with poor prognosis unless the neutrophil count recovers. In our patient, the neutrophil count fell below 100/mm 3 and remained at this level throughout the hospitalization course. In neutropenic patients, therapeutic outcome seems to be dependent on fungicidal drug activity. For trichosporonosis, as for aspergillosis, it is possible that combination therapy with drugs acting synergistically on different cell targets, such as caspofungin and amphotericin B, may overcome the problem of lack of fungicidal activity of antifungal agents when used alone.
Sir, Gum arabic is defined as the dried gummy exudate from the stems and branches of Acacia Senegal, Willdenow or other related African species of Acacia (Leguminosae). It is a complex of very high molecular weight acidic heteropolysaccharides, which is widely used in pharmaceutical preparations as a suspending, demulcent, soothing and emulsifying agent. It was reported that gum arabic increased faecal nitrogen excretion, decreased urea production and decreased urea-nitrogen recycling. 1 A study in animal models of experimental chronic renal failure showed that consumption of diets containing fermentable carbohydrates resulted in a greater faecal nitrogen excretion coupled with a reduction in serum urea concentration. 2 In 1996, Bliss et al. 3 reported that patients with chronic renal failure consuming a low-protein diet with 50 g gum arabic/day had a greater faecal nitrogen excretion and lower serum urea than patients consuming only a low-protein diet. Gum arabic is commonly prescribed for chronic renal failure in patients in Sudan; it results in decreased uraemia and reduces the frequency of dialysis, hence improving the quality of life. This study was conducted to investigate the effect of gum arabic on the absorption of amoxicillin, an antibiotic commonly prescribed for the treatment of urinary tract infections in patients with chronic renal failure.
The study design was open and randomized; 24 healthy adult volunteers were allocated into four groups, six in each group. They gave written consent. None of them had a history of hypersensitivity to penicillin. Ethical approval was obtained from the Sudanese Ethical Committee. In the control group (group I), a single oral dose of amoxicillin capsules 500 mg (SmithKline Beecham, Brentford, UK) was administered after 12 h overnight fasting; in the test groups the same dose of amoxicillin was given after 12 h overnight fasting as follows: concurrently with gum arabic (group II); 2 or 4 h after gum arabic ingestion (groups III and IV, respectively). Blood samples (5 mL) were taken at 0, 0.5, 1, 1.5, 2, 4 and 6 h after amoxicillin administration. The serum was separated and stored at À708C until assay, which was within 1 week of collection.
Determination of amoxicillin concentrations in the serum samples was carried out by a validated cup-plate agar diffusion method using Staphylococcus aureus (ATCC 25923) as the test organism. 4 The standard inoculum of the test organism was prepared as described by Cheesbrough. 5 The standard amoxicillin concentrations (0.25-8 mg/L) were prepared under aseptic conditions. All samples were assayed in quadruplicate in pooled human serum, and all the samples from each adult were analysed in parallel. The log of the known concentrations of amoxicillin standards was plotted against the mean inhibition zone diameter; it was linear over the concentration range studied with r 2 > 0.98. The within-day precision of replicate samples of 0.5 mg/L (n = 6) and 5.0 mg/L (n = 6) gave relative standard deviations of 2.5% and 1.1%. The day-to-day relative standard deviations for the standards 0.5 and 5 mg/L (n = 6) were 3.2% and 1.2%, respectively. The assay detection limit in serum was 0.02 mg/L.
Determination of the maximum peak concentration of amoxicillin (C max ) and the time it was attained (T max ) were obtained by visual inspection of individual patient data. The calculation
